Antibodies to Complex Receptors

描述(申请人提供)：ViraCore是一家生物技术公司，正在开发一种能够以纳米颗粒形式呈现复杂受体的药物发现工具。具体来说，ViraCore正在使用“脂粒”，即被脂质双层包围并嵌入膜结合受体的纳米颗粒，以提纯和溶解细胞表面的复杂受体，同时保持它们的结构完整性。这项建议的目的是利用脂质体开发针对膜结合受体构象复杂表位的单抗。我们要靶向的许多受体和表位很难，甚至在某些情况下，不可能用传统的方法来靶向，包括激活的受体构象和细胞内结构。脂肪制品为开发重要的新型抗体和候选疫苗提供了一种独特的技术。这一建议主要集中在趋化因子受体的抗体上，趋化因子受体是一类与HIV感染、艾滋病发病机制和免疫有关的膜结合受体。然而，这一提议的结果可以对针对各种复杂受体的抗体、疫苗和治疗的发展产生广泛的影响。

DESCRIPTION (provided by applicant): ViraCore is a biotechnology company that is creating a drug discovery tool that is capable of presenting complex receptors in a nanometer-sized particle format. Specific ally, ViraCore is using "lipoparticles", nanometer -sized particles surrounded by a lipid bilayer and embedded with membrane-bound receptors, to purify and solubilize complex receptors from the cell surface while maintaining their structuraI integrity. The purpose of this proposal is to use lipoparticles to develop monoclonal antibodies directed to conformationally complex epitopes of membrane- bound receptors. Many of the receptors and epitopes that we will target are difficult or, in some cases, impossible to target using traditional methods, including activated receptor conformations and intracellular structures. Lipoparticles present a unique technology for the development of important new classes of antibodies and vaccine candidates. This proposal focuses principally on antibodies to chemokine receptors, a class of membrane-bound receptors involved in HIV infection, AIDS pathogenesis, and immunity. However, the results of this proposal can have a broad impact on the development of antibodies, vaccines, and therapeutics against a wide variety of complex receptors.